Silodosin therapy for lower urinary tract symptoms in men with suspected benign prostatic hyperplasia: Results of an international, randomized, double-blind, placebo- and active-controlled clinical trial performed in Europe

European Urology

Volumn 59, Issue 3, 2011, Pages 342-352

  Chapple, Christopher R ^a   Montorsi, Francesco ^b   Tammela, Teuvo L J ^c   Wirth, Manfred ^d   Koldewijn, Evert ^e   Fernández Fernández, Eldiberto ^f  

^a ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

^b VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^c TAMPERE UNIVERSITY HOSPITAL   (Finland)

^d UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^e CATHARINA HOSPITAL   (Netherlands)

^f HOSPITAL RAMÓN Y CAJAL   (Spain)

Author keywords

BPH; LUTS; Silodosin; Tamsulosin

Indexed keywords

PLACEBO; SILODOSIN; TAMSULOSIN;

ADULT; AGED; ANXIETY DISORDER; ARTICLE; BLADDER NECK STENOSIS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; DRUG WITHDRAWAL; EJACULATION; EUROPE; HEART SUPRAVENTRICULAR ARRHYTHMIA; HUMAN; INTERNATIONAL PROSTATE SYMPTOM SCORE; LOWER URINARY TRACT SYMPTOM; MAJOR CLINICAL STUDY; MALE; MICTURITION; MULTICENTER STUDY; NOCTURIA; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; QUALITY OF LIFE; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RETROGRADE EJACULATION; SIDE EFFECT; TREATMENT RESPONSE; URINE FLOW RATE;

ADRENERGIC ALPHA-1 RECEPTOR ANTAGONISTS; AGED; DOUBLE-BLIND METHOD; EUROPE; HUMANS; INDOLES; MALE; MIDDLE AGED; NOCTURIA; PLACEBO EFFECT; PROSTATIC HYPERPLASIA; QUALITY OF LIFE; SULFONAMIDES; TREATMENT OUTCOME; URINATION; URINATION DISORDERS;

EID: 79551473561     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2010.10.046     Document Type: Article

References (37)

1. C. Chapple Medical treatment for benign prostatic hyperplasia BMJ 304 1992 1198 1199
2. G.M. Clifford, and R.D.T. Farmer Medical therapy for benign prostatic hyperplasia: a review of the literature Eur Urol 38 2000 2 19
3. M.J. Barry, A.T. Cockett, and H.L. Holtgrewe Relationship of symptoms of prostatism to commonly used physiological and anatomical measures of the severity of benign prostatic hyperplasia J Urol 150 1993 351 358
4. T.J. Peters, J.L. Donovan, and H.E. Kay The International Continence Society "Benign Prostatic Hyperplasia" Study: the botherosomeness of urinary symptoms J Urol 157 1997 885 889
5. S. Madersbacher, G. Alivizatos, J. Nordling, C. Rioja Sans, M. Emberton, and JJMC.H. de la Rosette EAU 2004 guidelines on assessment, therapy and follow-up of men with lower urinary tract symptoms suggestive of benign prostatic obstruction (BPH guidelines) Eur Urol 46 2004 547 554
6. H. Lepor Alpha blockers for the treatment of benign prostatic hyperplasia Rev Urol 9 2007 181 190
7. C.R. Chapple Pharmacological therapy of benign prostatic hyperplasia/lower urinary tract symptoms: an overview for the practicing clinician BJU Int 94 2004 738 744
8. H. Lepor, S. Auerbach, and A. Puras-Baez A randomised, placebo-controlled multicenter study of the efficacy and safety of terazosin in the treatment of benign prostatic hyperplasia J Urol 148 1992 1467 1474
9. C.R. Chapple, P. Carter, and T.J. Christmas A three-month double-blind study of doxazosin as treatment for benign prostatic bladder outlet obstruction J Urol 74 1994 50 56
10. Michel MC, Grübbel B, Möllhoff S, et al. 1-Adrenoceptor affinities of drugs for the treatment of benign prostatic hyperplasia in human prostate, rat tissues and at cloned subtypes. Abstract presented at: 23rd Congress of the Société Internationale d'Urologie; September 18-24, 1994; Sydney, Australia. Abstract 649.
11. 1-adrenoceptors subtypes mediating the contraction of human urethra and peripheral artery Br J Pharmacol 113 1994 723 728
12. S. Tatemichi, K. Kobayashi, and A. Maezawa α1-Adenoceptor subtype selectivity and organ specificity of silodosin (KMD-3213) Yakugaku Zasshi 126 2006 209 216
13. K. Akiyama, M. Hora, and S. Tatemichi KMD-3213, a uroselective and long-acting alpha(1a)-adrenoceptor antagonist, tested in a novel rat model J Pharmacol Exp Ther 291 1999 81 91
14. K. Akiyama, H. Noto, and O. Nishizawa Effect of KMD-3213, an alpha1A-adrenoceptor antagonist, on the prostatic urethral pressure and blood pressure in male decerebrate dogs Int J Urol 8 2001 177 183
15. K. Kawabe, M. Yoshida, Y. Homma Silodosin Clinical Study Group Silodosin, a new alpha1A-adrenoceptor-selective antagonist for treating benign prostatic hyperplasia: results of a phase III randomized, placebo-controlled, double-blind study in Japanese men BJU Int 98 2006 1019 1024
16. L.S. Marks, M.C. Gittelman, L.A. Hill, W. Volinn, and G. Hoel Rapid efficacy of the highly selective alpha1A-adrenoceptor antagonist silodosin in men with signs and symptoms of benign prostatic hyperplasia: pooled results of 2 phase 3 studies J Urol 181 2009 2634 2640
17. C. Chapple Andersson KE Tamsulosin: an overview World J Urol 19 2002 397 404
18. L.S. Marks, M.C. Gittelman, L.A. Hill, W. Volinn, and G. Hoel Silodosin in the treatment of the signs and symptoms of benign prostatic hyperplasia: a 9-month, open-label extension study Urology 74 2009 1318 1322
19. S. Kobayashi, Y. Tomiyama, S. Tatemichi, Y. Hoyano, M. Kobayashi, and Y. Yamazaki Effects of silodosin and tamsulosin on the urethra and cardiovascular system in young and old dogs with benign prostatic hyperplasia Eur J Pharmacol 613 2009 135 140
20. S.A. MacDiarmid, L.A. Hill, W. Volinn, and G. Hoel Lack of pharmacodynamic interaction of silodosin, a highly selective alpha1a-adrenoceptor antagonist, with the phosphodiesterase-5 inhibitors sildenafil and tadalafil in healthy men Urology 75 2010 520 525
21. M.M. van Dijk, de la Rosette JJMCH, and M.C. Michel Effects of alpha-1 adrenoceptor antagonists on male sexual function Drugs 66 2006 287 301
22. K. Furukawa, D.J. Rosario, D.J. Smith, C.R. Chapple, T. Uchiyama, and R. Chess-Williams Alpha 1A-adrenoceptor-mediated contractile responses of the human vas deferens Br J Pharmacol 116 1995 1605 1610
23. M.C. Michel, G. Hanft, and G. Groß Functional studies on alpha-1-adrenoceptor subtypes mediating inotropic effects in rat right ventricle Br J Pharmacol 111 1994 539 546
24. 1D-adrenoceptor subtypes Br J Pharmacol 120 1997 231 238
25. A. Leonardi, J.P. Hieble, and L. Guarneri Pharmacological characterization of the uroselective alpha-1 antagonist Rec 15/2739 (SB 216469): role of the alpha-1L adrenoceptor in tissue selectivity, part I J Pharmacol Exp Ther 281 1997 1272 1283
26. F.A. Giuliano, P. Clement, P. Denys, L. Alexandre, and J. Bernabe Comparison between tamsulosin and alfuzosin on the expulsion phase of ejaculation in rats BJU Int 98 2006 876 879
27. J. Miller, and C.C. Carson Alpha blockers and ejaculatory function: a state of the art review Curr Sex Health Rep 4 2007 141 144
28. A. Sanbe, Y. Tanaka, and Y. Fujiwara α1-Adrenoceptors are required for normal male sexual function Br J Pharmacol 152 2007 332 340
29. M.C. Michel α1-Adrenoceptors and ejaculatory function Br J Pharmacol 152 2007 289 290
30. S. Hisasue, R. Furuya, N. Itoh, K. Kobayashi, S. Furuya, and T. Tsukamoto Ejaculatory disorder caused by alpha-1 adrenoceptor antagonists is not retrograde ejaculation but a loss of seminal emission Int J Urol 13 2006 1311 1316
31. K. Kobayashi, N. Masumori, and S.I. Hisasue Inhibition of seminal emission is the main cause of anejaculation induced by a new highly selective α1A-blocker in normal volunteers J Sex Med 5 2008 2185 2190
32. W.J. Hellstrom, F. Giuliano, and R.C. Rosen Ejaculatory dysfunction and its association with lower urinary tract symptoms of benign prostatic hyperplasia and BPH treatment Urology 74 2009 15 21
33. M.H. Blanker, J.L. Bosch, and F.P. Groeneveld Erectile and ejaculatory dysfunction in a community-based sample of men 50-78 years old: prevalence, concern, and relation to sexual activity Urology 57 2001 763 768
34. M.H. Blanker, A.M. Bohnen, and F.P. Groeneveld Correlates for erectile and ejaculatory dysfunction in older Dutch men: a community- based study J Am Geriatr Soc 49 2001 436 442
35. R. Rosen, J. Altwein, and P. Boyle Lower urinary tract symptoms and male sexual dysfunction: the Multinational Survey of the Aging Male (MSAM-7) Eur Urol 44 2003 637 649
36. C.G. Roehrborn, H. Lepor, and S.A. Kaplan Retrograde ejaculation induced by silodosin is the result of relaxation of smooth musculature in the male urogenital tract and is associated with greater urodynamic and symptomatic improvement in male LUTS secondary to BPH J Urol 181 2009 Abstract 1922
37. Y. Homma, K. Kawabe, M. Takeda, and M. Yoshida Ejaculation disorder is associated with increased efficacy of silodosin for benign prostatic hyperplasia Urology 76 2010 1446 1450